Dr Reddy’s Laboratories has announced the commercial launch of 2-deoxy-D-glucose (2-DG), a drug for moderate to severe Covid-19 patients administered as an adjunct therapy to the existing standard care.
The emergency use approval for anti-Covid-19 therapeutic application of the drug was granted on May 1, 2021.
Also read:
Dr Reddy’s will supply to major government as well as private hospitals across India. In the initial weeks, the company will make the drug available in hospitals across metros and Tier 1 cities, and subsequently expand coverage to the rest of India.
2-DG manufactured by Dr Reddy’s has a purity of 99.5 per cent and is being sold commercially under the brand name 2-DG. The maximum retail price (MRP) of each sachet has been fixed at ₹990, with a subsidised rate offered to government institutions.
2-DG was developed by the Institute of Nuclear Medicine & Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy’s Labs.
The oral drug can be administered only upon prescription and under the supervision of a qualified physician to hospitalised patients.
Dr G Satheesh Reddy, Secretary - Department of Defence (R&D) and Chairman, DRDO, in a statement said: “We are pleased to have worked closely with our long-term industry partner Dr Reddy's Laboratories, Hyderabad, for testing 2-DG as therapeutic application in treatment of Covid-19 patients. DRDO has been contributing in the fight against Covid-19 pandemic with its spin-off technologies."
Satish Reddy, Chairman, Dr Reddy’s, said: “2-DG is yet another addition to our Covid-19 portfolio that already covers the full spectrum of mild to moderate and severe conditions and includes a vaccine. We are extremely pleased to have partnered with DRDO in our collective fight against the Covid-19 pandemic.”